INTRODUCTION {#s1}
============

Cancer, a major cause of human mortality, has been a worldwide public health problem. A variety of factors such as genetic lesions, environmental aspect and increasing adoption of unhealthy lifestyle are considered as crucial causes of cancer \[[@R1]\]. Among them, obesity is an important factor contributing to the occurrence and development of malignancies. According to the literature in 2005, 396 and 937 million people suffer from obese and overweight worldwide, respectively \[[@R2]\]. Epidemiological research reveals that obesity increases the risk of cancer with evidence that obese women have 50% higher incidence rate than normal weight women \[[@R3]\]. In the process of obesity, dysregulated circulating hormones and growth factors may play an important role in carcinogenesis \[[@R4]\]. Among them, aberrant adiponectin concentration is reported to be a vital link between obesity and cancer.

Adiponectin, firstly discovered by Scherer *et al.* in 1995, is an adipokine predominantly produced by adipocytes with the monomeric subunit containing 244 amino-acids in human and circulates abundantly in plasma \[[@R5], [@R6]\]. Three bioactive forms of adiponectin are produced after post-transcriptional process known as trimeric low molecular weight (90 kD, LMW), hexameric medium molecular weight (180 kD, MMW) and oligomeric high molecular weight (\> 400 kD, HMW) adiponectin. Among them, HMW-adiponectin is the dominant form in plasma and has the most biological activity than the other two isoforms \[[@R7]\]. Adiponectin mainly acts on two seven-transmembrane adiponectin receptors, AdipoR1 and AdipoR2. Besides, T-cadherin is also responsible for mediating the role of adiponectin in certain tissues \[[@R8], [@R9]\]. Adiponectin exerts pleiotropic functions in human health such as anti-inflammation, anti-atherosclerosis, and anti-angiogenesis. It also has the properties of insulin-sensitizing and balancing glucose and lipid metabolism in various cells \[[@R10]\]. A number of studies reveal that circulating adiponectin levels decrease in metabolic syndrome, whereas overexpression of it can counteract metabolic dysfunctions \[[@R10]\]. Besides, increased weight reduces the plasma adiponectin level and decreased weight upregulates circulating adiponectin level \[[@R11]\].

It was first reported that circulating adiponectin level was lower in patients with breast cancer in 2003 \[[@R12]\]. Since then, the most clinical studies have indicated that hypoadiponectinemia is associated with risk of various cancers including prostate, endometrial, and colorectal cancers \[[@R13]--[@R16]\]. In addition, adiponectin has anti-proliferative and pro-apoptotic effects on cultured cancer cell lines \[[@R17], [@R18]\]. These results suggest that adiponectin might be an important regulator in carcinogenesis and progression of cancers. However, unchanged or increased circulating adiponectin levels in pancreatic and hepatocellular carcinoma are also reported \[[@R19], [@R20]\]. Therefore, understanding the exact role of adiponectin in cancer may offer a novel target in tumor diagnosis and therapeutic strategy. In order to gain a more explicit and evidence-based conclusion on the association between circulating adiponectin levels and carcinogenesis, we conducted a comprehensive meta-analysis of current available studies.

RESULTS {#s2}
=======

Literature selection {#s2_1}
--------------------

The initial comprehensive search yielded 1486 articles, of which 235 articles were excluded for duplication. Then 997 studies were ruled out because of apparent irrelevance after reading titles and/or abstracts. The remaining 254 studies were included for full-text reading, of which 151 studies were removed for one of the following reasons: (i) reviews, comments or letters (n = 37); (ii) shared population (n = 13); (iii) no report of adiponectin levels and/or SDs for both patients and controls or there was not enough information to calculate them (n = 25); (iv) not case-control study (n = 76). 4 additional studies were included from checking the references list. Finally, 107 studies met the inclusion criteria and were used for further analysis \[[@R12], [@R13], [@R15], [@R16], [@R20]--[@R112]\]. The flow diagram of this selection process was showed in Figure [1](#F1){ref-type="fig"}.

![Flow diagram of the included studies](oncotarget-07-48671-g001){#F1}

Study characteristics {#s2_2}
---------------------

Among the 107 studies, a total of 25,675 controls and 19,319 cases were enrolled until August, 2015. Geographic regions were various, among which 46 studies from Asia, 39 studies from Europe, 19 studies from America, and 3 studies from Africa. 16 types of malignancies were investigated in this meta-analysis, with digestive system cancers accounting for the largest percentage (43 studies); other types included: breast cancer (20 studies), prostate cancer (13 studies), endometrial carcinoma (11 studies), lung cancer (5 studies), renal cancer (3 studies), acute leukemia (3 studies), non-Hodgkin\'s lymphoma (3 studies), Hodgkin\'s lymphoma (1 study), multiple myeloma (2 studies), melanoma (1 study), thyroid cancer (1 study), and tongue cancer (1 study). Circulating samples included serum (65 studies) and plasma (37 studies), while 5 studies did not mention the exact one. Most researches provided the mean concentrations of circulating adiponectin levels and the SDs of them. SDs from 11 studies were calculated based on the sample size and *P* values. 96 studies had NOS scores greater than 6 along with 11 studies had scores of 5. The main characteristics of eligible articles were listed in Table [1](#T1){ref-type="table"}.

###### Characteristics of all the included studies in the meta-analysis

  Author                  Year   Type                       Country          Ethnicity   Sample   Mean age (Case/control)   Number (Case/control)   Study design               Assay method   Assay source                               Study quality
  ----------------------- ------ -------------------------- ---------------- ----------- -------- ------------------------- ----------------------- -------------------------- -------------- ------------------------------------------ ---------------
  Petridou et al.         2006   Acute leukemia             Greece/USA       Caucasian   Serum    NR                        201/201                 Case-control               RIA            Beth Israsel Deaconess Medical Center      8
  Moschovi et al.         2010   Acute leukemia             Greece           Caucasian   Plasma   4.3/5.2                   9/9                     Prospective case-control   Other          Linco Research                             7
  Aref et al.             2013   Acute leukemia             Egypt            African     Serum    42.8/49.1                 80/20                   Case-control               Elisa          R&D Systems                                5
  Miyoshi et al.          2003   Breast cancer              Japan            Asian       Serum    54.0/52.8                 102/100                 Case-control               Elisa          NR                                         7
  Mantzoros et al.        2004   Breast cancer              Greece           Caucasian   Serum    NR                        174/167                 Case-control               RIA            Beth Israsel Deaconess Medical Center      8
  Chen et al.             2006   Breast cancer              Taiwan           Asian       Serum    49.9/48.9                 100/100                 Case-control               RIA            Linco Research                             7
  Korner et al.           2007   Breast cancer              Greece           Caucasian   Serum    62.5/55.6                 74/76                   Case-control               RIA            ALPCO Diagnostics                          7
  Kang et al.             2007   Breast cancer              Korea            Asian       Serum    47.4/47.8                 41/43                   Case-control               Elisa          AdipoGen                                   7
  Hou et al.              2007   Breast cancer              China            Asian       Serum    48/49                     80/50                   Case-control               Elisa          R&D Systems                                6
  Tworoger et al.         2007   Breast cancer              USA              Caucasian   Blood    57.1/58.1                 1166/1575               Nested case-control        RIA            Linco Research                             7
  Tworoger et al.         2007   Breast cancer              USA              Caucasian   Blood    45.4/45.1                 311/621                 Nested case-control        RIA            Linco Research                             7
  Hancke et al.           2010   Breast cancer              Switzerland      Caucasian   Serum    59.5/49.0                 159/41                  Case-control               Elisa          BioVendor Laboratory Medicine              6
  Cust et al.             2009   Breast cancer              Sweden           Caucasian   Plasma   52.5/NR                   561/561                 Case-control               RIA            Linco Research                             7
  Shahar et al.           2010   Breast cancer              Malaysia         Asian       Serum    47.3/46.2                 70/138                  Case-control               Elisa          Linco Research                             7
  Dalamaga et al.         2011   Breast cancer              Greece           Caucasian   Serum    61.5/62.8                 102/102                 Case-control               Elisa          Avibion                                    7
  Al Khaldi et al.        2011   Breast cancer              Kuwait           Asian       Plasma   49/60                     60/68                   Case-control               Elisa          Linco Research                             7
  Touvier et al.          2013   Breast cancer              France           Caucasian   Plasma   49.2/51.5                 218/436                 Nested case-control        Elisa          R&D Systems                                9
  Gulcelik et al.         2012   Breast cancer              Turkey           Asian       Serum    51.4/52.4                 83/40                   Case-control               Elisa          B-Bridge International Inc.                7
  Al Awadhi et al.        2012   Breast cancer              Kuwait           Asian       Plasma   50.3/50.7                 144/77                  Case-control               Elisa          Linco Research                             7
  Alokail et al.          2013   Breast cancer              Saudi Arabia     Asian       Serum    46.4/43.1                 56/53                   Case-control               Other          Luminex Corporation                        7
  Ollberding et al.       2013   Breast cancer              USA              Caucasian   Serum    67.8/67.8                 706/706                 Nested case-control        Elisa          R&D Systems                                8
  Gross et al.            2013   Breast cancer              USA              Caucasian   Plasma   62.6/62.5                 272/272                 Case-control               Elisa          ALPCO Diagnostics                          7
  Minatoya et al.         2014   Breast cancer              Japan            Asian       Serum    NR                        66/66                   Case-control               Other          SRL                                        7
  Gulcelik et al.         2012   Colon cancer               Turkey           Asian       Serum    52.1/52.4                 27/40                   Case-control               Elisa          B-Bridge International Inc.                7
  Otake et al.            2005   Colorectal adenoma         Japan            Asian       Plasma   59.0/58.0                 51/52                   Case-control               Elisa          Otsuka Pharmaceutical                      8
  Fukumoto et al.         2008   Colorectal adenoma         Japan            Asian       Plasma   NR                        656/648                 Case-control               Elisa          Otsuka Pharmaceutical                      7
  Kumor et al.            2009   Colorectal adenoma         Poland           Caucasian   Serum    62.4/60.1                 37/25                   Case-control               Elisa          R&D Systems                                7
  Erarslan et al.         2009   Colorectal adenoma         Turkey           Asian       Plasma   63.0/59.0                 31/50                   Case-control               Elisa          RayBio                                     8
  Nakajima et al.         2010   Colorectal adenoma         Japan            Asian       Plasma   66.8/66.7                 72/72                   Case-control               Elisa          Otsuka Pharmaceutical                      7
  Otake et al.            2010   Colorectal adenoma         Japan            Asian       Plasma   65.1/67.9                 47/26                   Case-control               Elisa          Otsuka Pharmaceutical                      7
  Yamaji et al.           2010   Colorectal adenoma         Japan            Asian       Plasma   NR                        778/735                 Case-control               Elisa          Sekisui Medical                            6
  Danese et al.           2013   Colorectal adenoma         Italy            Caucasian   Serum    63.0/59.5                 40/40                   Case-control               Elisa          Mediagnost                                 7
  Wei et al.              2005   Colorectal cancer          USA              Caucasian   Plasma   66.6/66.5                 179/356                 Nested case-control        RIA            Linco Research                             8
  Stocks et al.           2008   Colorectal cancer          Sweden           Caucasian   Plasma   59.7/NR                   306/595                 Nested case-control        Elisa          R&D Systems                                6
  Guadagni et al.         2009   Colorectal cancer          Italy            Caucasian   Serum    63.0/59.0                 90/30                   Case-control               Elisa          BioVendor Laboratory Medicine              8
  Kumor et al.            2009   Colorectal cancer          Poland           Caucasian   Serum    58.6/60.1                 36/25                   Case-control               Elisa          R&D Systems                                7
  Erarslan et al.         2009   Colorectal cancer          Turkey           Asian       Plasma   57.0/59.0                 23/50                   Case-control               Elisa          RayBio                                     8
  Nakajima et al.         2010   Colorectal cancer          Japan            Asian       Plasma   63.7/63.5                 115/115                 Case-control               Elisa          Otsuka Pharmaceutical                      7
  Otake et al.            2010   Colorectal cancer          Japan            Asian       Plasma   66.7/67.9                 51/26                   Case-control               Elisa          Otsuka Pharmaceutical                      7
  Kemik et al             2010   Colorectal cancer          Turkey           Asian       Serum    43.5/40.4                 126/38                  Case-control               RIA            Linco Research                             7
  Gonullu et al.          2010   Colorectal cancer          Turkey           Asian       Serum    56.6/51.0                 36/37                   Case-control               Elisa          BioSource                                  8
  Catalan et al.          2011   Colorectal cancer          Spain            Caucasian   Plasma   66.0/44.0                 11/18                   Case-control               Elisa          R&D Systems                                8
  Chen et al.             2012   Colorectal cancer          China            Asian       Plasma   61.9/58.3                 165/102                 Case-control               Elisa          Adlitteram Diagnostic Laboratories. Inc.   7
  Touvier et al.          2012   Colorectal cancer          France           Caucasian   Plasma   51.8/52.1                 50/100                  Nested case-control        Elisa          R&D Systems                                9
  Aleksandrova et al.     2012   Colorectal cancer          Germany          Caucasian   Serum    58.3/58.3                 1206/1206               Case-control               Elisa          ALPCO Diagnostics                          9
  Song et al.             2013   Colorectal cancer          USA              Caucasian   Plasma   61.9/61.9                 616/1205                Case-control               Elisa          ALPCO Diagnostics                          9
  Cust et al.             2007   Endometrical carcinoma     UK               Caucasian   Plasma   56.9/56.9                 284/548                 Nested case-control        Elisa          R&D Systems                                8
  Soliman et al.          2006   Endometrical carcinoma     USA              Caucasian   Serum    66.6/61.2                 117/238                 Case-control               Elisa          R&D Systems                                5
  Ashizawa et al.         2010   Endometrical carcinoma     Japan            Asian       Serum    59.9/57.5                 146/150                 Case-control               RIA            Linco Research                             8
  Dossus et al.           2013   Endometrical carcinoma     Germany          Caucasian   Serum    57.7/57.7                 233/446                 Case-control               Elisa          R&D Systems                                8
  Friedenreich et al.     2012   Endometrical carcinoma     USA              Caucasian   Serum    59/59                     514/962                 Case-control               Elisa          ALPCO Diagnostics                          9
  Luhn et al.             2013   Endometrical carcinoma     USA              Caucasian   Serum    NR                        167/327                 Nested case-control        RIA            Linco Research                             8
  Erdogan et al.          2013   Endometrical carcinoma     Turkey           Asian       Serum    56.6/49.7                 60/70                   Case-control               Elisa          eBioscience                                6
  Ma et al.               2013   Endometrical carcinoma     China            Asian       Serum    53.2/53.3                 206/310                 Case-control               Elisa          Bender MedSystems                          9
  Dallal et al.           2013   Endometrical carcinoma     USA              Caucasian   Serum    67.4/67.5                 62/124                  Nested case-control        Elisa          Millipore                                  8
  Mihu et al.             2013   Endometrical carcinoma     Romania          Caucasian   Serum    60.2/58.5                 44/44                   Case-control               Elisa          R&D Systems                                6
  Ohbuchi et al.          2014   Endometrical carcinoma     Japan            Asian       Serum    61.2/58.1                 43/62                   Case-control               Elisa          Daiichi Co. Ltd.                           8
  Diao et al.             2009   Esophageal cancer          China            Asian       Plasma   58.0/49.0                 43/33                   Case-control               Elisa          Adlitteram Diagnostic Laboratories. Inc.   6
  Nakajima et al.         2010   Esophageal cancer          Japan            Asian       Blood    63.6/63.6                 117/117                 Case-control               Elisa          Otsuka Pharmaceutical                      6
  Yildirim et al.         2009   Esophageal cancer          Turkey           Asian       Serum    64/61                     62/30                   Case-control               Elisa          Avibion                                    6
  Ishikawa et al.         2005   Gastric cancer             Japan            Asian       Plasma   64.2/59.3                 75/52                   Case-control               Elisa          Otsuka Pharmaceutical                      6
  Nakajima et al.         2009   Gastric cancer             Japan            Asian       Blood    61.0/60.8                 156/156                 Case-control               Elisa          Otsuka Pharmaceutical                      8
  Seker et al.            2010   Gastric cancer             Turkey           Asian       Plasma   60.0/38.6                 40/43                   Case-control               Elisa          Linco Research                             5
  Diakowska et al.        2014   Gastroesophageal cancer    Poland           Caucasian   Serum    60.0/58.0                 85/60                   Case-control               Elisa          R&D Systems                                7
  Kotani et al.           2009   Hepatacellular carcinoma   Japan            Asian       Serum    63.5/62.7                 59/334                  Nested case-control        Elisa          Daiichi Co. Ltd.                           8
  Liu et al.              2009   Hepatacellular carcinoma   Taiwan/China     Asian       Serum    50.7/53.8                 120/116                 Case-control               Elisa          B-Bridge International Inc.                5
  Sumie et al.            2011   Hepatacellular carcinoma   Japan            Asian       Serum    67.4/61.2                 97/97                   Case-control               Elisa          EikenChenical Co. Ltd.                     7
  Sadik et al             2012   Hepatacellular carcinoma   Egypt            African     Serum    58.9/55.7                 69/121                  Case-control               Elisa          Assaypro                                   7
  Chen et al.             2012   Hepatacellular carcinoma   Taiwan/China     Asian       Serum    52.4/52.2                 65/165                  Case-control               RIA            Linco Research                             6
  Khattab et al.          2012   Hepatacellular carcinoma   Egypt            African     Plasma   43.9/42.9                 147/320                 Case-control               Other          Linco Research                             5
  Chen et al.             2014   Hepatacellular carcinoma   Taiwan/China     Asian       Plasma   NR                        185/373                 Nested case-control        Elisa          B-Bridge International Inc.                8
  Petridou et al.         2010   Hodgkin lymphoma           Greece           Caucasian   Serum    11.5/11.2                 75/75                   Case-control               RIA            Linco Research                             7
  Jamieson et al.         2004   Lung cancer                UK               Caucasian   Serum    64.0/65.0                 20/13                   Case-control               RIA            Linco Research                             7
  Karapanagiotou et al.   2008   Lung cancer                Greece           Caucasian   Serum    64.2/55.5                 101/51                  Case-control               Elisa          BioVendor                                  6
  Petridou et al.         2007   Lung cancer                Greece           Caucasian   Serum    NR                        85/170                  Case-control               RIA            Beth Israsel Deaconess Medical Center      8
  Gulen et al.            2012   Lung cancer                Turkey           Asian       Serum    65.6/63.5                 63/25                   Case-control               Elisa          BioVendor                                  7
  Kerenidi et al.         2013   Lung cancer                Greece           Caucasian   Serum    62.9/NR                   80/40                   Case-control               Elisa          Linco Research                             7
  Antoniadis et al.       2011   Melanoma                   Greece/Canada    Caucasian   Serum    52.7/53.3                 55/165                  Case-control               RIA            Beth Israsel Deaconess Medical Center      8
  Dalamaga et al.         2009   Multiple myeloma           Greece/Canada    Caucasian   Serum    NR                        73/73                   Case-control               Elisa          Avibion                                    8
  Hofmann et al.          2012   Multiple myeloma           USA              Caucasian   Plasma   NR                        174/348                 Case-control               Elisa          R&D Systems                                7
  Pamuk et al.            2006   Non-Hodgkin\'s lymphoma    Turkey           Asian       Serum    63.2/58.5                 28/17                   Case-control               Elisa          OtsukaCo.Ltd                               5
  Petridou et al.         2009   Non-Hodgkin\'s lymphoma    Greece           Caucasian   Serum    8.8/8.8                   121/121                 Case-control               RIA            NR                                         7
  Conroy et al.           2013   Non-Hodgkin\'s lymphoma    USA              Caucasian   Plasma   70.0/70.0                 272/541                 Nested case-control        Elisa          R&D Systems                                7
  Chang et al.            2007   Pancreatic cancer          Taiwan/China     Asian       Serum    64.6/49.5                 72/290                  Case-control               Elisa          R&D Systems                                8
  Dalamaga et al.         2009   Pancreatic cancer          Greece           Caucasian   Serum    69.0/70.1                 81/81                   Case-control               RIA            Linco Research                             7
  Solomon et al.          2008   Pancreatic cancer          USA              Caucasian   Serum    58.0/58.0                 311/510                 Case-control               Elisa          Millipore                                  8
  Krechler et al.         2011   Pancreatic cancer          Czech Republic   Caucasian   Plasma   51.9/64.5                 64/64                   Case-control               RIA            DRG Inc.                                   8
  Grote et al.            2012   Pancreatic cancer          Germany          Caucasian   Serum    58.0/60.0                 452/452                 Nested case-control        Other          R&D Systems                                8
  Bao et al.              2013   Pancreatic cancer          USA              Caucasian   Plasma   NR                        468/1080                Nested case-control        Elisa          ALPCO Diagnostics                          8
  Goktas et al.           2005   Prostate cancer            Turkey           Asian       Plasma   65.8/62.2                 30/36                   Case-control               RIA            Linco Research                             8
  Goktas et al.           2005   Prostate cancer            Turkey           Asian       Plasma   65.8/65.0                 30/41                   Case-control               RIA            Linco Research                             8
  Baillargeon et al.      2006   Prostate cancer            USA              Caucasian   Serum    63.5/63.2                 125/125                 Nested case-control        Other          Luminex                                    7
  Michalakis et al.       2007   Prostate cancer            Greece           Caucasian   Serum    74.0/64.0                 75/150                  Case-control               RIA            Linco Research                             5
  Michalakis et al.       2007   Prostate cancer            Greece           Caucasian   Serum    74.0/70.0                 75/75                   Case-control               RIA            Linco Research                             5
  Housa et al.            2008   Prostate cancer            Czech Republic   Caucasian   Serum    63.6/70.5                 43/25                   Case-control               RIA            Linco Research                             5
  Grosman et al.          2010   Prostate cancer            Argentina        Caucasian   Serum    NR                        25/25                   Case-control               RIA            Linco Research                             7
  Li et al.               2010   Prostate cancer            USA              Caucasian   Plasma   59.0/58.6                 620/599                 Nested case-control        RIA            Linco Research                             7
  Dhillon et al.          2011   Prostate cancer            USA              Caucasian   Plasma   57.9/57.5                 1286/1267               Nested case-control        RIA            Linco Research                             8
  Lopez Fontana et al.    2011   Prostate cancer            Argentina        Caucasian   Serum    63.8/64.9                 35/35                   Case-control               Elisa          Linco Research                             6
  Al Khaldi et al.        2011   Prostate cancer            Kuwait           Asian       Plasma   59.0/60.0                 14/68                   Case-control               Elisa          Linco Research                             7
  Touvier et al.          2013   Prostate cancer            France           Caucasian   Plasma   54.9/51.5                 156/1024                Nested case-control        Elisa          R&D Systems                                9
  Tewari et al.           2013   Prostate cancer            India            Asian       Blood    66.5/65.7                 95/95                   Case-control               Other          NR                                         5
  Spyridopoulos et al.    2012   Renal cancer               Greece           Caucasian   Serum    61.5/60.7                 60/236                  Case-control               RIA            Beth Israsel Deaconess Medical Center      8
  Liao et al.             2013   Renal cancer               Finland/USA      Caucasian   Serum    57/57                     273/273                 Nested case-control        Elisa          Millipore                                  9
  Liao et al.             2013   Renal cancer               Canada/USA       Caucasian   Serum    NR                        768/917                 Case-control               Elisa          Millipore                                  9
  Mitsiades et al.        2011   Thyroid cancer             USA              Caucasian   Serum    51.2/55.4                 175/107                 Case-control               RIA            Beth Israsel Deaconess Medical Center      5
  Guo et al.              2013   Tongue cancer              China            Asian       Serum    57.2/52.7                 59/50                   Case-control               Elisa          Adipobiotech                               8

Abbreviations: NR, not reported; Elisa, enzyme-linked immunosorbent assay; RIA, radioimmunoassay.

Circulating adiponectin levels and carcinogenesis {#s2_3}
-------------------------------------------------

Data from 107 studies were analyzed in a random-effect model to compare circulating adiponectin levels in people with different cancers and controls. Results showed that circulating adiponectin levels in cancer cases were significantly lower than in the controls with a pooled SMD of −0.334 μg/ml (95% CI, −0.465 to −0.203, *P* = 0.000). Statistically significant amount of heterogeneity was observed across these studies (I^2^ = 97.6%, *P* \< 0.0001), so subgroup analysis was carried out next. These results were presented in Figure [2](#F2){ref-type="fig"}.

![Forest plot of studies in circulating total adiponectin and cancer risk\
The combined SMD and 95% CIs were calculated through a random-effect model.](oncotarget-07-48671-g002){#F2}

HMW-adiponectin is the dominant form of adiponectin in plasma and correlates with cardiovascular disease, insulin resistance, and obesity \[[@R7], [@R113], [@R114]\]. But few studies have evaluated the relationship between circulating HMW-adiponectin levels and cancer risk. We analyzed data from 8 studies in a random-effect model to compare circulating HMW-adiponectin levels in people with different cancers \[[@R33], [@R56], [@R58], [@R72], [@R83], [@R94], [@R107], [@R108]\]. Results showed that circulating HMW-adiponectin levels in cancer cases were significantly lower than in the controls with a pooled SMD of −0.502 μg/ml (95% CI, −0.957 to −0.047, *P* = 0.000), which is consistent with the results derived from total adiponectin levels. Statistically significant amount of heterogeneity was observed across these studies (I^2^ = 97.0%, *P* \< 0.0001). These results were presented in Figure [3](#F3){ref-type="fig"}.

![Forest plot of studies in circulating high molecular weight adiponectin and cancer risk\
The combined SMD and 95% CIs were calculated through a random-effect model.](oncotarget-07-48671-g003){#F3}

Subgroup analysis and meta-regression {#s2_4}
-------------------------------------

Stratified subgroup analysis was performed to evaluate the potential sources of heterogeneity including ethnicity, cancer type, study design, blood sample, assay method, study size, study quality and mean age of cancer patients (Table [2](#T2){ref-type="table"}). Lower levels of circulating adiponectin were observed in both Asian (SMD −0.555, 95% CI, −0.812 to −0.298) and Caucasian people (SMD −0.269, 95% CI, −0.400 to −0.138). Similar results were also presented in people with breast (SMD −0.334, 95% CI, −0.543 to −0.126), colorectal (SMD −0.496, 95% CI, −0.653 to −0.339), endometrial (SMD −0.594, 95% CI, −0.825 to −0.363), prostate (SMD −0.892, 95% CI, −1.345 to −0.438), thyroid (SMD −0.358, 95% CI, −0.601 to −0.116), tongue (SMD −1.172, 95% CI, −1.580 to −0.764), gastroesophageal (SMD −0.278, 95% CI, −0.553 to −0.004) cancer, multiple myeloma (SMD −0.621, 95% CI, −0.966 to −0.276), and acute leukemia (SMD −0.594, 95% CI, −0.825 to −0.363). Notably, circulating adiponectin levels were higher in the patients with hepatocellular cancer than in controls among 7 studies included (SMD 1.385, 95% CI, 0.240 to 2.530).

###### Subgroup analysis of the relationships between circulating adiponectin levels and study characteristics

  Characteristics             Number of studies                       Number (Case/control)                           SMD      95% CI             Heterogeneity (I2)
  --------------------------- --------------------------------------- ----------------------------------------------- -------- ------------------ --------------------
  **Ethnicity**                                                                                                                                   
  Caucasian                   58                                      14178/19758                                     −0.269   −0.400 to −0.138   96.8%
  Asian                       46                                      4845/5456                                       −0.555   −0.812 to −0.298   97.1%
  African                     3                                       296/461                                         1.821    −2.201 to 5.843    99.6%
  **Cancer Types**                                                                                                                                
  Acute leukemia              3                                       290/230                                         −2.236   −4.418 to −0.054   97.3%
  Multiple myeloma            2                                       247/421                                         −0.621   −0.966 to −0.276   69.7%
  Breast cancer               20                                      4545/5292                                       −0.334   −0.543 to −0.126   95.5%
  Colorectal cancers          23                                      4749/5591                                       −0.496   −0.653 to −0.339   91.3%
  Endometrial cancer          11                                      1876/3281                                       −0.594   −0.825 to −0.363   92.8%
  Prostate cancer             13                                      2609/3565                                       −0.892   −1.345 to −0.438   97.9%
  Thyroid cancer              1                                       175/107                                         −0.358   −0.601 to −0.116   NA
  Tongue cancer               1                                       59/50                                           −1.172   −1.580 to −0.764   NA
  Hepatocellular cancer       7                                       742/1526                                        1.385    0.240 to 2.530     99.2%
  Gastroesophageal cancer     7                                       578/491                                         −0.278   −0.553 to −0.004   78.1%
  Hodgkin lymphoma            1                                       75/75                                           0.28     −0.041 to 0.602    NA
  Non-Hodgkin lymphoma        3                                       421/679                                         0.316    −0.048 to 0.68     79.7%
  Lung cancer                 5                                       349/299                                         −0.085   −0.58 to 0.409     87.1%
  Melanoma                    1                                       55/165                                          −0.112   −0.418 to 0.193    NA
  Pancreatic cancer           6                                       1448/2477                                       0.037    −1.207 to 1.281    99.6%
  Renal cancer                3                                       1101/1426                                       0.021    −0.246 to 0.288    86.6%
  **Study Design**                                                                                                                                
  Case-control study          86                                      11965/14210                                     −0.346   −0.505 to −0.188   97.2%
  Nested case-control study   21                                      7354/11465                                      −0.290   −0.553 to −0.026   98.5%
  **Blood samples**                                                                                                                               
  Serum                       65                                      9171/11101                                      −0.335   −0.483 to −0.186   95.8%
  Plasma                      37                                      8303/12010                                      −0.238   −0.497 to 0.022    98.6%
  NR                          5                                       1845/2564                                       −1.072   −1.775 to −0.369   98.8%
  **Assay methods**                                                                                                                               
  RIA                         29                                      6190/7587                                       −0.316   −0.459 to −0.172   93.0%
  Elisa                       71                                      12179/16968                                     −0.266   −0.426 to −0.106   97.4%
  Others                      7                                       950/1120                                        −1.305   −3.113 to 0.502    99.5%
  **Study size**                                                                                                                                  
  ≥100 patients               48                                      16057/21437                                     −0.135   −0.299 to-0.030    98.3%
  \<100 patients              59                                      3262/4238                                       −0.549   −0.825 to −0.273   96.5%
  **Study quality**                                                                                                                               
  ≥6                          96                                      16352/22425                                     −0.334   −0.465 to −0.203   97.3%
  \<6                         11                                      2967/3250                                       −0.267   −0.700 to 0.165    98.2%
  **Patients' age (mean)**                                                                                                                        
  ≥60                         44[\*](#tfn_001){ref-type="table-fn"}   4770/6414[\*](#tfn_001){ref-type="table-fn"}    −0.489   −0.689 to −0.288   95.6%
  \<60                        47[\*](#tfn_001){ref-type="table-fn"}   9782/12935[\*](#tfn_001){ref-type="table-fn"}   −0.194   −0.383 to −0.004   97.7%

Abbreviations: NA, not assessable.

There are 91 studies with 14,552 cases and 19,349 controls reported the mean age of cancer patients.

Additionally, adiponectin was significantly lower in patients who used serum as test samples (SMD −0.335, 95% CI, −0.483 to −0.186), and in 37 studies who used plasma as testing samples, 26 studies showed the inverse relation of adiponectin to cancer risk. Assay method (radioimmunoassay or enzyme-linked immunosorbent assay) did not affect the results that circulating adiponectin was lower in cancer patients with pooled SMD of −0.316 and −0.266. Study size (more or less than 100 patients) did not change the result of estimated SMD either (SMD −0.135, 95% CI, −0.299 to −0.030; SMD −0.549, 95% CI, −0.825 to −0.273, respectively). Besides, no matter the mean age of cancer patients is older or younger than 60 years, decreased adiponectin levels were still exist in cancer patients (SMD −0.489, 95% CI, −0.689 to −0.288; SMD −0.194, 95% CI, −0.383 to −0.004, respectively).

Next we performed meta-regression to evaluate the effect of the above factors on the estimate of SMD. In meta-regression, none of the examined factors, such as ethnicity, cancer type, study design, blood sample, assay method, study size, study quality and mean age of cancer patients was proved to be significant contributing factors.

Sensitivity analysis {#s2_5}
--------------------

Sensitivity analysis was performed by excluding one study at a time and calculating the pooled SMDs for the remaining studies. It was found that the combined SMDs were similar to one another and statistically significant. None of the studies influence the pooled results substantially in this analysis (Table [3](#T3){ref-type="table"}).

###### The pooled SMDs and 95% CIs of the included studies through sensitivity analysis

  Study omitted                  Estimate      95% CI
  ------------------------------ ------------- --------------------------
  Miyoshi et al. (2003)          −0.33362126   −.46549249 to −.20175007
  Jamieson et al. (2004)         −0.32790136   −.45929646 to −.19650623
  Mantzoros et al. (2004)        −0.3366529    −.46877834 to −.20452745
  Goktas et al. (2005)           −0.31018904   −.44067159 to −.1797065
  Goktas et al. (2005)           −0.31467217   −.4453963 to −.18394804
  Wei et al. (2005)              −0.33543056   −.46779135 to −.20306975
  Otake et al. (2005)            −0.32370359   −.45491788 to −.19248928
  Ishikawa et al. (2005)         −0.33179379   −.4634814 to −.20010617
  Petridou et al. (2006)         −0.33611172   −.4683494 to −.20387407
  Baillargeon et al. (2006)      −0.33559188   −.46757615 to −.2036076
  Chen et al. (2006)             −0.32800215   −.45950019 to −.1965041
  Pamuk et al. (2006)            −0.34167045   −.47312284 to −.21021806
  Soliman et al. (2006)          −0.32821506   −.45972851 to −.19670163
  Cust et al. (2007)             −0.33429027   −.46701819 to −.20156233
  Korner et al. (2007)           −0.33221245   −.4639549 to −.20046999
  Kang et al. (2007)             −0.33505732   −.46672907 to −.20338558
  Tworoger et al. (2007)         −0.33802846   −.47386777 to −.20218913
  Tworoger et al. (2007)         −0.3405844    −.47277904 to −.20838977
  Chang et al. (2007)            −0.35825887   −.48626736 to −.2302504
  Michalakis et al. (2007)       −0.32968622   −.46133375 to −.19803868
  Michalakis et al. (2007)       −0.33015183   −.46179458 to −.19850905
  Hou et al. (2007)              −0.33114624   −.46280947 to −.19948301
  Petridou et al. (2007)         −0.33918613   −.47100937 to −.20736288
  Fukumoto et al. (2008)         −0.33727011   −.47093907 to −.20360115
  Solomon et al. (2008)          −0.3375347    −.47031215 to −.20475723
  Housa et al. (2008)            −0.33494586   −.46656513 to −.2033266
  Karapanagiotou et al. (2008)   −0.337192     −.46895465 to −.20542936
  Stocks et al. (2008)           −0.33803195   −.47080877 to −.20525511
  Dalamaga et al. (2009)         −0.34321341   −.47464448 to −.21178232
  Dalamaga et al. (2009)         −0.32902971   −.46060005 to −.19745934
  Petridou et al. (2009)         −0.34161058   −.47322133 to −.2099998
  Kotani et al. (2009)           −0.33791459   −.46976718 to −.20606196
  Guadagni et al. (2009)         −0.31941918   −.45032975 to −.18850861
  Kumor et al. (2009)            −0.32856214   −.46004361 to −.1970806
  Erarslan et al. (2009)         −0.33168712   −.46326634 to −.20010787
  Kumor et al. (2009)            −0.3339898    −.4655939 to −.2023856
  Erarslan et al. (2009)         −0.33251002   −.46413583 to −.20088424
  Cust et al. (2009)             −0.33854863   −.47171903 to −.20537826
  Nakajima et al. (2009)         −0.33416247   −.4662253 to −.20209965
  Diao et al. (2009)             −0.33897933   −.47058302 to −.2073756
  Yildirim et al. (2009)         −0.3268407    −.45826575 to −.19541568
  Li et al. (2009)               −0.34737712   −.47806501 to −.21668923
  Moschovi et al. (2010)         −0.31926209   −.45011383 to −.18841037
  Hancke et al. (2010)           −0.33801222   −.46974581 to −.20627865
  Seker et al. (2010)            −0.34004903   −.47163537 to −.2084627
  Nakajima et al. (2010)         −0.33507797   −.46703228 to −.20312366
  Petridou et al. (2010)         −0.33972663   −.47141987 to −.20803338
  Grosman et al. (2010)          −0.32690996   −.45831883 to −.19550107
  Li et al. (2010)               −0.3373847    −.47090244 to −.20386696
  Nakajima et al. (2010)         −0.3372006    −.46912611 to −.2052751
  Otake et al. (2010)            −0.3304036    −.46196187 to −.19884537
  Kemik et al (2010)             −0.3278496    −.45933568 to −.19636351
  Gonullu et al. (2010)          −0.3353405    −.46698609 to −.20369488
  Nakajima et al. (2010)         −0.33436027   −.46614832 to −.20257224
  Ashizawa et al. (2010)         −0.33154425   −.4634259 to −.19966258
  Shahar et al. (2010)           −0.3222657    −.4640207 to −.20043245
  Otake et al. (2010)            −0.3297922    −.46132797 to −.19825645
  Yamaji et al. (2010)           −0.33636427   −.47040036 to −.20232819
  Antoniadis et al. (2011)       −0.3360277    −.46786067 to −.2041948
  Dhillon et al. (2011)          −0.33877328   −.47420669 to −.20333987
  Al Khaldi et al. (2011)        −0.3581396    −.48865175 to −.22762746
  Sumie et al. (2011)            −0.33623996   −.46812296 to −.20435697
  Catalan et al. (2011)          −0.3270525    −.4584052 to −.19569978
  Dalamaga et al. (2011)         −0.33432293   −.46621501 to −.20243084
  Al Khaldi et al. (2011)        −0.34966454   −.48045498 to −.21887414
  Krechler et al. (2011)         −0.33685401   −.46860847 to −.20509957
  Mitsiades et al. (2011)        −0.33370164   −.46567562 to −.20172767
  Lopez Fontana et al. (2011)    −0.3409504    −.47248313 to −.20941767
  Spyridopoulos et al. (2012)    −0.33505121   −.46693206 to −.20317033
  Hofmann et al. (2012)          −0.33265379   −.46483427 to −.2004733
  Gulen et al. (2012)            −0.33108562   −.46266881 to −.1995024
  Sadik et al (2012)             −0.35871589   −.48782459 to −.2296071
  Chen et al. (2012)             −0.32368076   −.45458078 to −.1927807
  Gulcelik et al. (2012)         −0.32346013   −.45471603 to −.19220424
  Aleksandrova et al. (2012)     −0.33816311   −.47353563 to −.20279059
  Friedenreich et al. (2012)     −0.33428073   −.46782497 to −.20073651
  Touvier et al. (2012)          −0.3405067    −.47251758 to −.20849583
  Gulcelik et al. (2012)         −0.31726849   −.44793424 to −.18660273
  Al Awadhi et al. (2012)        −0.34153      −.47313255 to −.2099274
  Grote et al. (2012)            0.33630246    −.46936187 to −.20324306
  Chen et al. (2012)             −0.34161338   −.47320184 to −.2100249
  Khattab et al. (2012)          −0.38207525   −.50227177 to −.2618787
  Dossus et al. (2013)           −0.33401754   −.46652448 to −.20151059
  Bao et al. (2013)              −0.30136451   −.41626969 to −.18645933
  Guo et al. (2013)              −0.3258861    −.45724642 to −.1945257
  Touvier et al. (2013)          −0.33433828   −.46610662 to −.2025699
  Liao et al. (2013)             −0.33713764   −.46957946 to −.20469585
  Liao et al. (2013)             −0.3403554    −.47350773 to −.20720309
  Conroy et al. (2013)           −0.33808553   −.47072488 to −.2054462
  Touvier et al. (2013)          −0.3296572    −.46145904 to −.19785538
  Kerenidi et al. (2013)         −0.3439351    −.4753255 to −.21254471
  Danese et al. (2013)           −0.34142008   −.47294763 to −.20989256
  Song et al. (2013)             −0.33765575   −.47181916 to −.20349233
  Luhn et al. (2013)             −0.33139816   −.46341154 to −.19938481
  Ma et al. (2013)               −0.32076678   −.45034227 to −.1911912
  Dallal et al. (2013)           −0.33651593   −.4683443 to −.20468754
  Alokail et al. (2013)          −0.30377382   −.43343174 to −.17411587
  Ollberding et al. (2013)       −0.33671638   −.47059336 to −.20283943
  Gross et al. (2013)            −0.33571425   −.46818775 to −.20324075
  Aref et al. (2013)             −0.31502652   −.4457356 to −.18431742
  Tewari et al. (2013)           −0.28841972   −.41580069 to −.16103874
  Erdogan et al. (2013)          −0.33102214   −.46268752 to −.19935676
  Mihu et al. (2013)             −0.3298324    −.46139839 to −.1982664
  Chen et al. (2014)             −0.33950841   −.47162384 to −.20739301
  Ohbuchi et al. (2014)          −0.33285877   −.46454135 to −.20117618
  Minatoya et al. (2014)         −0.32982665   −.46143582 to −.19821748
  Diakowska et al. (2014)        −0.33376125   −.46553349 to −.20198898
  Combined                       −0.33375105   −.46467104 to −.20283107

Publication bias {#s2_6}
----------------

Publication bias was assessed by funnel plot and Egger\'s regression test. Funnel plot shapes demonstrated a marginally asymmetrical distribution (Figure [4](#F4){ref-type="fig"}), accordingly we performed further analysis with Egger\'s test. The tested result (Figure [5](#F5){ref-type="fig"}) showed no evidence of publication bias (*P* = 0.123).

![Funnel plot of lower adiponectin expression and cancer risk\
Circles indicate included studies.](oncotarget-07-48671-g004){#F4}

![Egger\'s linear regression test for publication bias detection](oncotarget-07-48671-g005){#F5}

DISCUSSION {#s3}
==========

By integrating 107 studies, our meta-analysis revealed that lower circulating adiponectin levels were associated with higher risk of cancers. Despite the existence of heterogeneity, the disparity of adiponectin levels between malignant individuals and controls reveals the potential ability of adiponectin to serve as a biomarker for early detection of cancers.

Aberrant adiponectin secretion is associated with tumor progression, metastasis and overall prognosis. Two previous meta-analysis indicated that lower adiponectin levels were associated with higher risk of breast cancer, colorectal cancer and colorectal adenoma \[[@R115], [@R116]\]. By synthesizing 107 studies involving 19,319 cases with different malignancies, the present meta-analysis estimate the inverse association between circulating adiponectin levels and cancer risk. Moreover, through subgroup analysis, we identified that this inverse relation of adiponectin to cancer risk might be more meaningful in breast, colon, endometrial, prostate, and gastroesophageal cancers. Besides, adiponectin levels tend to decrease as tumor stage increases in gastric cancer \[[@R62]\]. Kang et al. also indicate that breast cancer patients with less than the median adiponectin levels are easy to develop lymph node metastasis \[[@R82]\]. Low adiponectin level is the independent predictor of unfavorable prognosis in colorectal cancer \[[@R117]\]. These findings demonstrate that adiponectin is not only associated with cancer risk, but also correlated with tumor progression. Additionally, in our included 107 studies, 8 studies evaluated the relationship between circulating levels of adiponectin subtypes and cancer risk. The changing trend of total adiponectin was almost same with the three adiponectin subtypes in cancer patients, especially with HMW-adiponectin, that it is inversely associated with cancer risk.

Circulating adiponectin levels are affected by various factors, including inflammatory, dietary, hormonal, genetic, and medicine. One of possible explanations for decreased adiponectin levels in malignancies is the sustained inflammatory status of cancer patients leads to the increased proinflammatory cytokines such as TNF-α and IL-6, which are all reported to suppress adiponectin transcription and translation in adipocyte cell line \[[@R118], [@R119]\]. Besides, in obesity-related cancers, adiponectin may control its own production through a negative feedback loop during the development of obesity \[[@R120]\]. Moreover, dietary with lower intake of fiber and magnesium can also reduce circulating adiponectin levels \[[@R121]\].

However, elevated adiponectin levels are also reported in hepatocellular carcinoma. Since adiponectin is mainly degraded in the liver and adiponectin levels are elevated in advanced disease including cirrhosis and virus-related cancer \[[@R61], [@R122]\]. One possible explanation for increased adiponectin level in hepatocellular carcinoma might be due to deteriorated hepatic metabolism resulted from repeated necroinflammation and regeneration. Besides, conflicting results also exist in clinical studies of pancreatic cancer that both higher and lower adiponectin levels are reported to be associated with cancer risk \[[@R45], [@R50]\]. After reviewing the pancreatic cancer studies with higher levels of adiponectin, we found that almost half of them were accompanied with jaundice \[[@R45]\]. Since cholestasis would lead to the chronic liver deterioration, it is possible that increased adiponectin levels might be due to the reduced degradation.

The peripheral functions of adiponectin are mainly mediated through AdipoR1 and AdipoR2. The expression levels of AdipoRs vary between malignant tissues and their peritumoral normal counterparts. The upregulation of AdipoR1 and AdipoR2 are reported in gastric carcinoma \[[@R123]\], whereas decreased in prostate cancer tissues compared with the nonmalignant tissues \[[@R36]\]. Increased expression of AdipoRs may be the response of reduced circulating as well as local adiponectin levels and reduced expression suggests that the sensitivity of AdipoRs to adiponectin is decreased in tumor tissues. Yabushita et al. indicate that poor expression of AdipoR1 is associated with tumor invasion and lymph node metastasis, as well as poor prognosis in endometrial cancer patients \[[@R124]\]. A study of non-small cell lung cancer also indicates that patients with higher expression of AdipoR1 have longer overall survival and AdipoR2 expression is inversely correlated with tumor size \[[@R125]\]. Those findings further illustrate the protective role of adiponectin as well as AdipoRs and shed light on exploiting them for cancer therapy. Recently, AdipoRs agonist called 355ADP is identified and might represent a new strategy to replace low adiponectin level in cancer \[[@R126]\].

Despite the inverse correlation between adiponectin and various cancers, the underlying mechanisms of adiponectin in potential cancer suppression are still need to elucidate. Adiponectin decreases low density lipoprotein (LDL) receptor expression in breast cancer cells through promoting autophagic flux and inhibits LDL-cholesterol-induced tumor cell proliferation \[[@R127]\]. Adiponectin induces the phosphorylation of p53, a tumor suppressor, which renders cell cycle arrest and apoptosis in cancer cell lines \[[@R128]\]. Adiponectin also inhibits leptin-induced metastasis by downregulating JAK/STAT3 pathway, displaying an inverse correlation with cancer development \[[@R129]\]. In contrast, adiponectin promotes the angiogenesis in human chondrosarcoma by increasing vascular endothelial growth factor-A expression \[[@R130]\]. It is also reported to exert anti-apoptotic effects on pancreatic cancer cells through activation of AMPK/Sirtuin-1 signaling pathway \[[@R131]\]. Taken together, adiponectin might play a complicated role in carcinogenesis and progression of cancers.

Our study has some limitations that need to be addressed when interpreting the results. The significant heterogeneity was observed among the studies thus the conclusion should be more conservative. Although stratified analysis was conducted, none of the factors including ethnicity, cancer type, study design, blood sample, assay method, study size, study quality, and mean age of cancer patients were confirmed to contributing factors. Some possible reasons may partially explain this heterogeneity. Adiponectin levels are changed along with the tumor development. The tumor type, size, histological grade, and lymph node metastasis are the possible contributors caused heterogeneity. It is difficult for us to acquire the detailed information from the included studies. Besides, the subjects were from different regions and the lifestyle combined with diet was varied, which might influence the level of adiponectin. Since adiponectin is mainly secreted from adipose tissue, variables such as age, hormone receptor expression, menopausal status and BMI could contribute to the secretion and those factors were not fully deliberated for the complexity of tumor environment.

CONCLUSIONS {#s4}
===========

In summary, the present study shows significant difference in circulating adiponectin levels between patients with malignancies and controls. Low circulating adiponectin level is associated with increased cancer risk, which suggests that adiponectin may serve as a potential biomarker for early detection of cancers considering its abundance in blood. Thorough understanding the roles of adiponectin and its receptors in the progression of cancers is helpful to cancer screening and promote individualized treatment.

MATERIALS AND METHODS {#s5}
=====================

Search strategy {#s5_1}
---------------

Based on the standard guidelines, a systematic search of English literature from Cochrane library, Wiley online library, PubMed was conducted to retrieve eligible studies until August 8, 2015. Searching terms included Medical Subject Heading (Mesh) and free text words "adiponectin", "ADPN", "Acrp 30", "AdipoQ", "GBP 28" or "apM1" in combination with "neoplasm", "cancer", "carcinoma", "malignancy" or "tumor". Furthermore, we manually searched references of relevant studies to add potential research to this meta-analysis.

Inclusion and exclusion criteria {#s5_2}
--------------------------------

Studies were included if they met the following criteria: (i) full text case-control studies published in peer-reviewed journals evaluating the relationship between circulating adiponectin concentration and carcinogenesis; (ii) all cases were diagnosed as cancer by pathological biopsy or other medical methods with blood sample obtained before any therapies and all the controls were people without any cancers. (iii) circulating adiponectin level and standard deviation (SD) of it were provided or there were enough information to estimate them. Reviews, letters or animal experiments were excluded and articles without key information to carry on further analysis were also beyond consideration. Meanwhile, if replicated patient cohort was published in different studies, only the most recent or complete one was chosen. Since all the studies included were acquired from literature, ethics committee approval was not needed.

Data extraction {#s5_3}
---------------

Based on the checklist of MOOSE (Meta-analysis Of Observational Studies in Epidemiology) \[[@R132]\], two reviewers (Tai W and Peng Y) extracted the following data independently from eligible studies: the last name of first author, year of publication, geographic region, ethnicity, tumor type, study design, sample type, adiponectin assay method, number of patients and controls, assay source, mean ± SD of adiponectin concentration. Disagreement was resolved by discussion until the two reviewers reached a consensus.

Quality assessment of included studies {#s5_4}
--------------------------------------

Two reviewers (Tai W and Peng Y) independently assessed the quality of each included study according to the Newcastle-Ottawa Quality Assessment Scale (NOS) \[[@R133]\] ranges from 0 to 9 stars. Studies with more than 6 stars were considered as high-quality studies. Any disagreement was resolved by discussion and reevaluation.

Statistical analysis {#s5_5}
--------------------

We acquired the mean ± SD of circulating adiponectin levels from cases and controls through three ways. The most accurate method was extracted them from the original research directly. However, a few studies presented the results as median values or standard error. In that case, we regarded median value as mean value considering the large sample size and calculated the SD value by using standard error and population number. If necessary, we contacted the author for detailed information. Standard mean differences (SMDs) and the corresponding 95% confidence intervals (CIs) of circulating adiponectin were calculated for all the eligible studies. Cochran\'s Q-test was performed to test the heterogeneity of included studies and *P* \< 0.05 was considered statistically significant. Higgins I-squared statistic was applied to offer evidence of heterogeneity with I^2^ \> 50% suggesting significant heterogeneity. The pooled SMD and 95% CI was calculated using a fixed-effects model if the heterogeneity was not significant, otherwise a random-effect model was employed and subgroup analyses and meta-regression were adopted to detect the potential cause of heterogeneity.

Sensitivity analysis was executed to detect the robustness of the results. Publication bias was evaluated by use of funnel plot and Egger\'s linear regression test. The Stata 13.0 software (Stata Corporation, College Station, TX, USA) was used to perform all the statistical analysis. All *P* values were two-sided.
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